Lindsay Fischer

Freshta Poupal, RN, and Frannie Bell, NP, share their experiences with teclistamab in clinical practice.

An initiative led by nurses helped reduce operating-room pressure injuries and saved their institution an estimated $80,210 per year.

The FDA has approved pembrolizumab in combination with chemotherapy as a treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

The Oncology Care Model did not significantly improve care, yet patients were satisfied with their care and many oncologists overcame their hesitancy towards value-based models.

In a survey, 75% of Black respondents said that racism had impacted their mental health in the workplace.

The FDA has approved toripalimab, with cisplatin and gemcitabine, and as a monotherapy, to treat adults with nasopharyngeal carcinoma.

Ivosidenib, a targeted therapy, has been approved for patients with relapsed or refractory myelodysplastic syndromes and an IDH1 mutation.

Adjuvant alectinib significantly improved disease-free survival in patients with ALK-positive, early-stage, non–small-cell lung cancer.

The Health Resources and Services Administration has announced that it will be investing in the training of new nurses and growing the workforce.

Capmatinib and tepotinib are highly selective kinase inhibitors targeting MET.

The FDA has granted priority view to osimertinib plus chemotherapy based on data from the phase 3 FLAURA2 trial.

Many Americans with health insurance are not fully covered for frontline procedures to treat lymphedema—a debilitating condition that often affects patients with cancer.

The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.

Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.

Clinical navigators helped increase the rate of genomic testing referrals among Black patients with prostate cancer—a group that faces significant health disparities in the care system.

Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.

The FDA has approved encorafenib plus binimetinib to treat adults with metastatic non-small cell lung cancer with a BRAF V600E mutation.

Nivolumab plus chemotherapy offers patients with gastric and esophageal cancers a reduced risk of symptom burden and a longer time to deterioration.

Hyperthermic intraperitoneal chemotherapy, also known as hot chemotherapy bath, showed a long-term overall survival improvement in patients with stage III primary epithelial ovarian cancer.

Noël Arring, PhD, DNP, RN, and Debra L. Barton, PhD, RN, FAAN, FASCO, discuss clinical strategies to address sexual dysfunction in female cancer survivors.

Chemotherapy shortages are affecting patients across the country.

Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.

Sarita M. Taylor, BSN, RN, OCN, shares how she mentally recharges outside of the clinic.

The FDA has granted marketing authorization to the Invitae Common Hereditary Cancers Panel, which can detect multiple genetic variants associated with hereditary cancers.

Patients with early breast cancer may safely choose a shorter course of radiation therapy following reconstruction.

The FDA has granted priority review to odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Meredith Donahue, APRN-BC, discusses emerging therapies in metastatic prostate cancer.

Stephanie Russell, DNP, AGNP-C, highlights the importance of gender-neutral language in the oncology environment.